clofibrate has been researched along with Hyperlipoproteinemias in 81 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Hyperlipoproteinemias: Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The long term effect of clofibrate treatment on the carbohydrate and lipid metabolisms and on insulin secretion was studied in subjects with primary hyperlipoproteinemia and impaired glucose tolerance." | 7.66 | Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period. ( Bruns, W; Ratzmann, KP; Ratzmann, ML; Rjasanowski, I, 1983) |
| "The effect of a combination of clofibrate and inositol nicotinate (Liporeduct forte, Liporeduct) on lipids and lipoproteins in 20 patients with primary hyperlipoproteinemia (10 type IIa, 7 type IV and 3 tyV) was investigated over a period of 16 weeks." | 7.66 | [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1983) |
| "The effect of long-term treatment over 40 weeks with Bezafibrate on lipids and lipoproteins was investigated in 27 patients with primary hyperlipoproteinemias (hlp) (12 patients with hlp type IV, 7 patients with type IIb, 3 patients with type IIa, 4 patients with type V and 1 patient with type III)." | 7.66 | [Bezafibrate in primary hyperlipidemias (author's transl)]. ( Bode, G; Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1982) |
| "Pirozadil and alufibrate are compared by a single-blind study over two groups 20 patients with primary hyperlipoproteinemia." | 7.66 | [Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias]. ( Azanza Perea, JR; Honorato Pérez, J, 1982) |
| "Clofibrate has cholesterol- and triglyceride-lowering effect." | 6.39 | [Clofibrate treatment of hyperlipoproteinemia]. ( Midorikawa, H; Oikawa, S, 1994) |
| " In type IIa etofylline clofibrate shows a good effect on total cholesterol and on the cholesterol fractions, both with regard to the collective treated and to the low dosage of 750 mg/d etofylline clofibrate compared to the usual dosage of 1500 mg clofibrate." | 5.26 | [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)]. ( Hausmann, L; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980) |
| "A total of 98 patients selected and classified into type IIa and IIb hyperlipoproteinemia according to Fredrickson and Lees (1965) were pre-treated for 6 months with a commercially available combination product (containing clofibrate and nicotinic acid)." | 5.05 | [Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug]. ( Steger, W, 1980) |
| "The long term effect of clofibrate treatment on the carbohydrate and lipid metabolisms and on insulin secretion was studied in subjects with primary hyperlipoproteinemia and impaired glucose tolerance." | 3.66 | Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period. ( Bruns, W; Ratzmann, KP; Ratzmann, ML; Rjasanowski, I, 1983) |
| "The effect of a combination of clofibrate and inositol nicotinate (Liporeduct forte, Liporeduct) on lipids and lipoproteins in 20 patients with primary hyperlipoproteinemia (10 type IIa, 7 type IV and 3 tyV) was investigated over a period of 16 weeks." | 3.66 | [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1983) |
| "The effect of long-term treatment over 40 weeks with Bezafibrate on lipids and lipoproteins was investigated in 27 patients with primary hyperlipoproteinemias (hlp) (12 patients with hlp type IV, 7 patients with type IIb, 3 patients with type IIa, 4 patients with type V and 1 patient with type III)." | 3.66 | [Bezafibrate in primary hyperlipidemias (author's transl)]. ( Bode, G; Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1982) |
| "Pirozadil and alufibrate are compared by a single-blind study over two groups 20 patients with primary hyperlipoproteinemia." | 3.66 | [Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias]. ( Azanza Perea, JR; Honorato Pérez, J, 1982) |
| "In a single-blind study the lipid-lowering drug gemfibrozil was compared at fixed dosage of 1600 mg daily with placebo and other drugs (mainly clofibrate) over a nine month period in 33 patients with hyperlipidaemia." | 2.65 | The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate. ( Nye, ER; Sutherland, WH; Temple, Wa, 1980) |
| "Twenty-two patients suffering from hyperlipidemia and receiving therapy consisting of a lipid-lowering diet and clofibrate (1 g X 2) were in addition given colestipol hydrochloride (5 g X 3) (Colestid, Upjohn) in a randomized, cross-over study for 2 periods of 6 weeks." | 2.65 | The effects of colestipol when combined with clofibrate in the treatment of severe hyperlipidemia. Short-term and long-term studies. ( Boberg, J; Hellsing, K; Lithell, H; Vessby, B, 1980) |
| "Both bezafibrate and EPL were tolerated well." | 2.65 | [Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)]. ( Bruneder, H; Klein, HJ, 1981) |
| "Clofibrate has cholesterol- and triglyceride-lowering effect." | 2.39 | [Clofibrate treatment of hyperlipoproteinemia]. ( Midorikawa, H; Oikawa, S, 1994) |
| "Ciprofibrate is a phenoxyisobutyrate derivative with lipid-lowering effects in hyperlipoproteinaemia." | 1.27 | Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia. ( Angelin, B; Einarsson, K; Leijd, B, 1984) |
| "Eruptive and tubero-eruptive xanthomas arising at the site of previous minor skin injury are described in two patients with type IV and type III hyperlipidemia, respectively." | 1.27 | Eruptive and tubero-eruptive xanthomas of the skin arising on sites of prior injury. Two case reports. ( Davignon, J; Roederer, G; Xhignesse, M, 1988) |
| "Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia." | 1.27 | Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986) |
| "Ciprofibrate was convenient to take and was without subjective side effects." | 1.26 | Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. ( Olsson, AG; Orö, L, 1982) |
| "Niceritrol treatment was associated with increased blood glucose, decreased K value, elevated fasting serum insulin and serum insulin at 60 min during IVGTT." | 1.26 | Changes in glucose tolerance and plasma insulin during lipid-lowering treatment with diet, clofibrate and niceritrol. ( Hellsing, K; Lithell, H; Vessby, B, 1982) |
| " The recommended dosage of clofibrate is 1." | 1.26 | [Fat and renal failure--therapeutic aspects]. ( Heidland, A; Hörl, M; Hörl, WH, 1982) |
| " In type IIa etofylline clofibrate shows a good effect on total cholesterol and on the cholesterol fractions, both with regard to the collective treated and to the low dosage of 750 mg/d etofylline clofibrate compared to the usual dosage of 1500 mg clofibrate." | 1.26 | [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)]. ( Hausmann, L; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980) |
| "Clofibrate treatment resulted in a reduction of plasma cholesterol, hepatic HMG-CoA reductase and cholesterol 7 alpha-hydroxylase activities." | 1.26 | Effect of probucol on cholesterol metabolism in the rat. ( Holets, RJ; Kottke, BA; Li, JR, 1980) |
| "Niceritrol treatment significantly reduced the Chol/TG ratio in VLDL while no such effect was seen during clofibrate administration." | 1.26 | Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease. ( Borberg, J; Gustafsson, IB; Lithell, H; Vessby, B, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 73 (90.12) | 18.7374 |
| 1990's | 8 (9.88) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keen, H | 1 |
| Lewis, B | 1 |
| Miller, NE | 1 |
| Wynn, V | 1 |
| Kaffarnik, H | 3 |
| Schneider, J | 4 |
| Schubotz, R | 3 |
| Zöfel, P | 2 |
| Hausmann, L | 2 |
| Goebel, KM | 1 |
| Donatelli, L | 1 |
| Walther, A | 1 |
| Mordasini, R | 1 |
| Riesen, W | 1 |
| Ratzmann, ML | 1 |
| Rjasanowski, I | 1 |
| Bruns, W | 1 |
| Ratzmann, KP | 1 |
| Słowińska, R | 1 |
| Bochenek, W | 1 |
| Unlot, J | 1 |
| Romics, L | 3 |
| Angelin, B | 2 |
| Einarsson, K | 2 |
| Leijd, B | 2 |
| Hanefeld, M | 2 |
| Hora, C | 1 |
| Schulze, J | 1 |
| Rothe, G | 1 |
| Barthel, U | 1 |
| Haller, H | 1 |
| Pados, G | 1 |
| Kusztos, D | 1 |
| Németh-Csóka, M | 1 |
| Valyon, M | 1 |
| Farkas, K | 1 |
| Hutt, V | 2 |
| Wechsler, JG | 2 |
| Klör, HU | 2 |
| Ditschuneit, H | 2 |
| Schatton, W | 2 |
| Schlierf, G | 1 |
| Fischer, H | 1 |
| Roche, A | 1 |
| Stiehl, A | 1 |
| Oster, P | 1 |
| Schellenberg, B | 1 |
| Vollmar, J | 2 |
| Gries, FA | 1 |
| Prager, R | 1 |
| Schernthaner, G | 1 |
| Kostner, GM | 1 |
| Mühlhauser, I | 1 |
| Zechner, R | 1 |
| Dorda, W | 1 |
| Reuter, W | 3 |
| Coffman, JD | 1 |
| Rasmussen, HM | 1 |
| Kemmer, C | 1 |
| Kadner, E | 1 |
| Nye, ER | 1 |
| Sutherland, WH | 1 |
| Temple, Wa | 1 |
| Olsson, AG | 1 |
| Orö, L | 1 |
| Machalke, K | 1 |
| Djaja, S | 1 |
| Richter, E | 1 |
| Pickering, JE | 1 |
| Lageder, H | 1 |
| Lithell, H | 3 |
| Vessby, B | 3 |
| Boberg, J | 1 |
| Hellsing, K | 2 |
| Tan, MH | 1 |
| Dick, TB | 1 |
| Marples, J | 1 |
| Ledermann, HM | 1 |
| Whittington, J | 1 |
| Fiegel, G | 1 |
| von Bock und Polach, U | 1 |
| Bode, G | 1 |
| Mertz, DP | 1 |
| Lang, PD | 1 |
| Heller, F | 1 |
| Honorato Pérez, J | 1 |
| Azanza Perea, JR | 1 |
| Hörl, WH | 1 |
| Hörl, M | 1 |
| Heidland, A | 1 |
| Mühlfellner, G | 2 |
| Mühlfellner, O | 1 |
| Vorberg, G | 1 |
| Ziegler, WJ | 1 |
| Padrón, RS | 1 |
| Amaro, S | 1 |
| Hung, S | 1 |
| Licea, M | 1 |
| Giorcelli, G | 1 |
| Vacha, G | 1 |
| Icardi, GP | 1 |
| Sale, JK | 1 |
| Johnstone, JH | 1 |
| Bruneder, H | 1 |
| Klein, HJ | 1 |
| Padosh, D | 1 |
| Kustosh, D | 1 |
| Puchok, I | 1 |
| Dem'ianova, N | 1 |
| Audikovski, M | 1 |
| Arteaga, A | 1 |
| Maiz, A | 1 |
| Lathrop, R | 1 |
| Szondy, E | 1 |
| Gerö, S | 1 |
| Weisweiler, P | 2 |
| Schwandt, P | 2 |
| Schwartzkopff, W | 2 |
| Schilling, A | 2 |
| Calder, D | 1 |
| Steger, W | 1 |
| Chevrel, B | 1 |
| Li, JR | 1 |
| Holets, RJ | 1 |
| Kottke, BA | 1 |
| Jarillo, MD | 1 |
| Coca, MC | 1 |
| Díaz Rubio, C | 1 |
| Bello, I | 1 |
| Gutiérrez-Millet, V | 1 |
| Ruilope, LM | 1 |
| Rodicio, JL | 1 |
| Alvarez Ude, F | 1 |
| Noseda, G | 1 |
| Fragiacomo, C | 1 |
| Weidmann, P | 1 |
| Bachmann, C | 1 |
| Ducobu, J | 1 |
| Oikawa, S | 1 |
| Midorikawa, H | 1 |
| Wilczek, H | 1 |
| Sobra, J | 3 |
| Ceska, R | 3 |
| Justová, V | 1 |
| Procházková, R | 2 |
| Kvasilová, M | 2 |
| Jůzová, Z | 1 |
| Toschnerová, H | 1 |
| Traurig, J | 1 |
| Fruchart, JC | 1 |
| Brewer, HB | 1 |
| Leitersdorf, E | 1 |
| Gustafsson, IB | 1 |
| Borberg, J | 1 |
| Neureuther, G | 1 |
| Bolzano, K | 1 |
| Krempler, F | 1 |
| Haslauer, F | 1 |
| Kollár, J | 1 |
| Rozdobud'ková, V | 1 |
| Koprovicová, J | 1 |
| Rajnová, E | 1 |
| Seiler, J | 1 |
| Kłosiewicz-Latoszek, L | 1 |
| Szostak, WB | 1 |
| Hunninghake, DB | 1 |
| Rywik, S | 1 |
| Roederer, G | 1 |
| Xhignesse, M | 1 |
| Davignon, J | 2 |
| Blum, CB | 1 |
| Levy, RI | 1 |
| Postiglione, A | 1 |
| Riccardi, G | 1 |
| Saldalamacchia, G | 1 |
| Stuyt, PM | 1 |
| Brown, WV | 1 |
| Holm, E | 1 |
| Parker, F | 1 |
8 reviews available for clofibrate and Hyperlipoproteinemias
| Article | Year |
|---|---|
[Pharmacology of probucol. I].
Topics: Adult; Aged; Animals; Anticholesteremic Agents; Chemical Phenomena; Chemistry; Cholesterol; Clofibra | 1984 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Drug treatment of hyperlipoproteinaemia.
Topics: Body Weight; Clofibrate; Gonadal Steroid Hormones; Humans; Hyperlipoproteinemias; Hypolipidemic Agen | 1983 |
HDL-cholesterol: the negative risk factor for coronary heart disease.
Topics: Adult; Age Factors; Alcoholism; Child; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Clofibra | 1980 |
[Clofibrate treatment of hyperlipoproteinemia].
Topics: Cholesterol; Clofibrate; Humans; Hyperlipoproteinemias; Lipoprotein Lipase; Lipoproteins; Liver; Tri | 1994 |
Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group.
Topics: Animals; Cholesterol, LDL; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hydroxymethylg | 1998 |
Drug treatment of dyslipoproteinemia.
Topics: Bile Acids and Salts; Clofibrate; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; | 1990 |
[Basic principles of drug therapy of hyperlipoproteinemia].
Topics: Adult; Anticholesteremic Agents; Cholesterol; Clofibrate; Humans; Hyperlipoproteinemias; Hypolipidem | 1988 |
16 trials available for clofibrate and Hyperlipoproteinemias
| Article | Year |
|---|---|
[Study of the antilipemic effect of etofibrate (Lipo-Merz)].
Topics: Adult; Aged; Anticholesteremic Agents; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Female; | 1983 |
[Pharmacology and mechanism of action of etofibrate].
Topics: Animals; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemias; Hypoli | 1982 |
[The effect of bezafibrate on biliary lipids (author's transl)].
Topics: Adult; Bezafibrate; Bile; Clofibrate; Clofibric Acid; Drug Evaluation; Humans; Hyperlipoproteinemias | 1980 |
Effect of bezafibrate on plasma lipids, lipoproteins, apolipoproteins AI, AII and B and LCAT activity in hyperlipidemic, non-insulin-dependent diabetics.
Topics: Aged; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Bezafibrate; Chole | 1982 |
The peripheral circulation and treatment of hyperlipoproteinemias.
Topics: Adult; Aged; Arteriosclerosis Obliterans; Blood Circulation; Clofibrate; Colestipol; Female; Humans; | 1983 |
The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
Topics: Adult; Aged; Cholesterol; Clofibrate; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Lipoprotei | 1980 |
[Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Clofibr | 1982 |
[Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia].
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemias; Male; P | 1980 |
The effects of colestipol when combined with clofibrate in the treatment of severe hyperlipidemia. Short-term and long-term studies.
Topics: Alkaline Phosphatase; Cholesterol; Clofibrate; Colestipol; Drug Therapy, Combination; Female; Humans | 1980 |
Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia.
Topics: Adult; Aged; Alkaline Phosphatase; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; C | 1981 |
[Therapeutic effect of etofyllinclofibrate in disordered lipid and uric acid metabolism].
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibrate; Female; Humans; Hy | 1982 |
[Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
Topics: Clofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia | 1980 |
[Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
Topics: Adult; Aged; Bezafibrate; Blood Glucose; Cholesterol; Clofibrate; Clofibric Acid; Diabetes Complicat | 1981 |
[Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Drug Combinations | 1980 |
[Is hypolipemic treatment effective as a preventive measure?].
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Clofibrat | 1989 |
Hypolipidemic effects of bezafibrate: studies in Italy.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Humans; Hyperlipoproteinemia | 1986 |
57 other studies available for clofibrate and Hyperlipoproteinemias
| Article | Year |
|---|---|
Clofibrate and hyperlipidaemia.
Topics: Clofibrate; Diabetic Retinopathy; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Ty | 1980 |
Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Creatine Kinase; Female; gamma-Glutamyltransfe | 1980 |
[Changes in serum lipoproteins in kidney diseases. Therapeutic possibilities].
Topics: Clofibrate; Dietary Fats; Energy Metabolism; Humans; Hyperlipoproteinemias; Kidney Failure, Chronic; | 1983 |
Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period.
Topics: Adult; Blood Glucose; Cholesterol; Clofibrate; Follow-Up Studies; Glucose Tolerance Test; Humans; Hy | 1983 |
Effect of ciprofibrate treatment on biliary lipids in patients with hyperlipoproteinaemia.
Topics: Adult; Aged; Bile; Bile Acids and Salts; Cholesterol; Clofibrate; Clofibric Acid; Female; Fibric Aci | 1984 |
Reduced incidence of cardiovascular complications and mortality in hyperlipoproteinemia (HLP) with effective lipid correction. The Dresden HLP study.
Topics: Adolescent; Adult; Cerebrovascular Disorders; Cholesterol; Cholestyramine Resin; Clofibrate; Combine | 1984 |
Favourable effect of combined Miscleron-Xavin treatment on HDL-cholesterol level.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Drug Therapy, Combination; Humans; Hyperlipoproteine | 1983 |
Consensus conference: Treatment of hypertriglyceridemia.
Topics: Body Weight; Cardiovascular Diseases; Clofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipopro | 1984 |
[Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Topics: Clofibrate; Drug Combinations; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; H | 1983 |
[Longterm therapy and etofibrate (author's transl)].
Topics: Anticholesteremic Agents; Blood Cell Count; Blood Glucose; Clofibrate; Clofibric Acid; Drug Administ | 1980 |
[Drug therapy of hypertriglyceridemias (author's transl)].
Topics: Clofibrate; Humans; Hyperlipoproteinemias; Nicotinic Acids; Triglycerides | 1980 |
Clofibrate treatment and bile cholesterol saturation: short-term and long-term effects and influence of combination with chenodeoxycholic acid.
Topics: Adult; Aged; Bile; Chenodeoxycholic Acid; Cholesterol; Clofibrate; Drug Therapy, Combination; Female | 1981 |
[Effect of combination therapy of clofibric acid and nicotinic acid derivatives on fatty acid metabolism in hyperlipoproteinemia].
Topics: Aged; Clofibrate; Clofibric Acid; Drug Therapy, Combination; Fatty Acids; Female; Humans; Hyperlipop | 1982 |
Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man.
Topics: Adult; Aged; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemias; Male; Microbodies; M | 1983 |
Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Sedimentation; Body Weight; Cholesterol; Ch | 1982 |
Nutritional & pharmacologic management of hyperlipoproteinemia.
Topics: Cholesterol; Cholesterol, Dietary; Clofibrate; Dietary Fats; Gemfibrozil; Humans; Hyperlipoproteinem | 1982 |
Changes in glucose tolerance and plasma insulin during lipid-lowering treatment with diet, clofibrate and niceritrol.
Topics: Aged; Arteriosclerosis; Blood Glucose; Body Weight; Clofibrate; Dietary Carbohydrates; Female; Gluco | 1982 |
[Lowering lipids rapidly and permanently with etofibrate].
Topics: Cholestyramine Resin; Clofibrate; Clofibric Acid; Dextrothyroxine; Humans; Hyperlipoproteinemias; Li | 1982 |
[Bezafibrate in primary hyperlipidemias (author's transl)].
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Female; Hu | 1982 |
Bezafibrate: lack of effect on creatinine excretion and muscular proteins.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Creatine Kinase; Creatinine; Female; Humans; Hyperlipoprote | 1982 |
[Clofibrate therapy--the status quo].
Topics: Carcinogens; Cholelithiasis; Cholesterol; Clofibrate; Humans; Hyperlipoproteinemias; Lipoproteins, L | 1982 |
[Should clofibrate still be prescribed?].
Topics: Adult; Animals; Cardiovascular Diseases; Cholesterol; Clofibrate; Cricetinae; Humans; Hyperlipoprote | 1982 |
[Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias].
Topics: Cholesterol; Clofibrate; Clofibric Acid; Drug Evaluation; Female; Humans; Hyperlipoproteinemias; Lip | 1982 |
[Fat and renal failure--therapeutic aspects].
Topics: Acute Kidney Injury; Animals; Bezafibrate; Carnitine; Charcoal; Clofibrate; Clofibric Acid; Humans; | 1982 |
[Current treatment with clofibrate or clofibric acid (Regadrin)].
Topics: Cholelithiasis; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hypercholesterolemia; Hyperlipoprot | 1982 |
[What is important in therapy of hyperlipoproteinemia. Lipo-Merz retard (etofibrate) lowers the atherogenic index].
Topics: Anticholesteremic Agents; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Humans; Hyperlipo | 1982 |
[On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
Topics: Cholesterol; Clofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipids; Lipoproteins; | 1980 |
[Association of vasopressin-sensitive diabetes insipidus with hyperlipoproteinemia].
Topics: Adolescent; Adult; Clofibrate; Diabetes Insipidus; Female; Humans; Hyperlipoproteinemias; Male; Midd | 1981 |
Drug treatment of hypertriglyceridaemia in chronic uraemic patients: preliminary report on D,L-carnitine and thiadenol.
Topics: Carnitine; Chronic Disease; Clofibrate; Fatty Alcohols; Humans; Hyperlipoproteinemias; Lipid Metabol | 1980 |
Pre- and post-treatment values of HDL cholesterol and total: HDL cholesterol ratio in hyperlipoproteinaemic subjects.
Topics: Cholesterol; Cholesterol, HDL; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipopr | 1981 |
[Effect of diet and drug therapy on the level of high density lipoprotein cholesterol in patients with primary hyperlipoproteinemia].
Topics: Biguanides; Cholesterol; Cholesterol, HDL; Clofibrate; Dietary Fats; Humans; Hyperlipoproteinemias; | 1981 |
[Hyperlipoproteinemias: experience of out-patient treatment of 112 patients (author's transl)].
Topics: Body Weight; Cholesterol; Cholestyramine Resin; Clofibrate; Humans; Hyperlipoproteinemias; Hypolipid | 1981 |
[Effect of clofibrate therapy on serum lipids and lipoproteins].
Topics: Clofibrate; Humans; Hyperlipoproteinemias; Lipids; Lipoproteins; Male; Middle Aged | 1980 |
[Lipoproteins and hyperlipoproteinemias].
Topics: Blood Protein Disorders; Cholesterol; Cholestyramine Resin; Clofibrate; Diet Therapy; Humans; Hyperl | 1980 |
[Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
Topics: Blood Glucose; Cholesterol; Clofibrate; Creatinine; Delayed-Action Preparations; Humans; Hyperlipopr | 1980 |
[Chenodeoxycholic acid. Indications in biliary pathology and hyperlipoproteinemias].
Topics: Bile Duct Diseases; Chenodeoxycholic Acid; Cholelithiasis; Cholesterol; Clofibrate; Dilatation, Path | 1980 |
Effect of probucol on cholesterol metabolism in the rat.
Topics: Animals; Body Weight; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Clofibrate; Hydroxymethylglutary | 1980 |
[Low dose clofibrate in the treatment of hypertriglyceridemia in hemodialysis patients (author's transl)].
Topics: Adolescent; Adult; Clofibrate; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Kidney F | 1980 |
[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlip | 1980 |
Creatinekinase in hyperlipoproteinemic patients treated with clofibrate.
Topics: Clofibrate; Creatine Kinase; Female; Humans; Hyperlipoproteinemias; Male; Middle Aged; Muscular Dise | 1980 |
[Comparative research on etofibrate retard and fenofibrate in hyperlipoproteinemia].
Topics: Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Female; Fenofibrate; Hum | 1980 |
[Physiopathology of hyperlipidemias, practical approach (author's transl)].
Topics: Adult; Clofibrate; Diet Therapy; Humans; Hyperlipoproteinemias; Lipoproteins; Middle Aged | 1980 |
[Therapy with fibrates and vitamin D metabolism].
Topics: Adult; Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; M | 1993 |
[Duolip Forte--experience during a 6-month period of administration].
Topics: Adult; Aged; Clofibrate; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle A | 1993 |
Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
Topics: Adult; Aged; Arteriosclerosis; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipopr | 1979 |
Serum lipoprotein lipids after gemfibrozil treatment.
Topics: Adult; Aged; Cholesterol; Clofibrate; Humans; Hyperlipoproteinemias; Lipoproteins; Lipoproteins, HDL | 1979 |
[Treatment of various types of hyperlipoproteinaemia with a combination of Mg-chlorophenoxy-isobutyrate and mesoinositol-hexanicotinate (author's transl)].
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Drug Combinations; Female; Humans; Hyperlipopr | 1979 |
[Is Etolip suitable for treatment of various types of hyperlipoproteinemias?].
Topics: Adult; Clofibrate; Humans; Hyperlipoproteinemias; Lipids; Middle Aged | 1991 |
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; | 1991 |
[Etolip and Lipanthyl in the treatment of hyperlipoproteinemia].
Topics: Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle A | 1990 |
Eruptive and tubero-eruptive xanthomas of the skin arising on sites of prior injury. Two case reports.
Topics: Adult; Clofibrate; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; M | 1988 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem | 1986 |
Rational drug therapy of the hyperlipoproteinemias, Part II.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Female; Fish Oils; Gemfibrozil; Human | 1986 |
[Drugs in hyperlipidemia].
Topics: Cholestyramine Resin; Clofibrate; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemi | 1987 |
Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Topics: Clofibrate; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hy | 1987 |
[Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Dietary Fats; Female; Humans; Hyperlipoprotein | 1986 |
Xanthomas and hyperlipidemias.
Topics: Apoproteins; Arteriosclerosis; Cholestasis; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyr | 1985 |